Easton Pharmaceuticals Announces Neil Mellor as Senior Consultant, Chief
TORONTO -- June 5, 2013
Easton Pharmaceuticals (OTC: EAPH), a specialty pharmaceutical company that
designs, develops, and markets a premium array of topically-delivered
therapeutic healthcare products, announced today that Mr. Neil Mellor will
join the company as Senior Consultant, Chief Operations Officer. Mr. Mellor
has over 25 years of experience in the pharmaceutical industry, both in Canada
and Europe. The majority of Mr. Mellor’s background is in sales, marketing and
business development for companies such as Merck, Pharmacia (now Pfizer), and
Solvay Pharma (now Abbott Laboratories).
Over the past 10 years, Mr. Mellor has been Associate Director of Business
Development at Solvay Pharma. In addition, Mr. Mellor served as President of
the Canadian Healthcare Licensing Association (CHLA) from 2007 to 2008 and
remains an active member of the Board of the CHLA. Mr. Mellor is currently the
President of Global Health Link, a healthcare consulting company serving
Canadian and US clients. We are especially pleased to have such an
accomplished professional as Mr. Mellor on board to help with our future plans
for our products, beginning with our lead product VIORRA^TM,” commented Mr.
John Adams, of Easton Pharmaceuticals’. "Mr. Mellor’s vast experience in
marketing and licensing will help us navigate the sometimes uncertain waters
of the different markets Easton Pharmaceuticals is considering, and will help
us focus on the design and execution of key business activities which will
enrich our pending commercialization efforts.”
About Easton Pharmaceuticals Inc
Easton Pharmaceuticals is a specialty pharmaceutical company that designs,
develops, and markets a premium array of topically-delivered therapeutic
healthcare products, focused on skin and circulatory conditions that impact a
large and expanding numbers of consumers including health issues related to
male and female sexual dysfunction, scar and stretch marks, cellulite and
varicose veins. The world market for these conditions is in excess of US$10
The company's proprietary gel formulation is an innovative and unique
transdermal delivery system. Easton Pharmaceuticals’ flagship product, VIORRA,
is an over-the-counter aid to help restore and improve vaginal moisture and
elasticity which plays an important role in women’s sexual desire and arousal
, FSAD (Female Sexual Arousal Disorder). The world market for products which
treat this disorder is in excess of US$2 billion. VIORRA is a topical,
daily-use product classified by the US Food and Drug Administration (FDA) as
containing Generally Recognized as Safe ingredients.
For more information, visit http://www.eastonpharma.com or
Easton Pharmaceuticals Inc.
Tel: +1(416) 619-0291
Tel: +1(347) 284-0192
Email and Media Relations: firstname.lastname@example.org
Email and Media Relations: email@example.com
Easton Pharmaceuticals Inc.
Dragoslav Milanovic, CEO
Press spacebar to pause and continue. Press esc to stop.